Publications

Estimating rates of Omicron-associated COVID-19 outcomes in a population-based cohort of people with HIV in Ontario, Canada, compared with a matched cohort of people without HIV

To better understand why acetylsalicylic acid (ASA/Aspirin) decreased the proportion of FGT HIV target cells by 35 % by analyzing if ASA reduces inflammation through downregulation of oxylipins.

To report on timeliness to study initiation, enrolment, compliance and retention rates of a prospective, randomized pilot study with participants with HIV, aged ≥18 and on antiretroviral therapy and randomly assigned to cannabidiol (CBD) ± Δ9-tetrahydrocannabinol (THC) capsules for 12 weeks with the primary objective being to assess safety and tolerability.

The objective of this study was to compare the socioeconomic, clinical and vaccine immune response correlates of BTI following two and three doses of COVID-19 vaccines in a prospective Canadian cohort of PWH enrolled in a vaccine immunogenicity study.

The international randomized clinical trial REPRIEVE has shed light on the reduction of cardiovascular diseases with statin therapy among people living with HIV so this article critically reviewed studies aimed at lipid-lowering and immune-modulating roles of statins that may benefit aging people living with HIV.

Considering the experiences of women with HIV in Canada over the past decade.

Considering GMB’s definitions of sexual health to improve service provision

To examine associations between 4 CD4 count measures as indicators of immune function and infection-related and infection-unrelated cancer risk in people living with HIV.

To identify novel correlates of subclinical CAA, markers of intestinal damage and cell trafficking/inflammation, in people living with HIV receiving antiretroviral therapy in the Canadian HIV/Aging Cohort study.

Considering the prevalence of M. genitalium infections among Montréal gbMSM.